Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash & Equivalents (2016 - 2025)

Abeona Therapeutics has reported Cash & Equivalents over the past 15 years, most recently at $78.4 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $78.4 million for Q4 2025, up 231.03% from a year ago — trailing twelve months through Dec 2025 was $78.4 million (up 231.03% YoY), and the annual figure for FY2025 was $78.4 million, up 231.03%.
  • Cash & Equivalents for Q4 2025 was $78.4 million at Abeona Therapeutics, down from $82.9 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for ABEO hit a ceiling of $163.9 million in Q2 2025 and a floor of $5.0 million in Q1 2023.
  • Median Cash & Equivalents over the past 5 years was $17.1 million (2024), compared with a mean of $32.2 million.
  • Biggest five-year swings in Cash & Equivalents: soared 431.29% in 2021 and later crashed 87.19% in 2022.
  • Abeona Therapeutics' Cash & Equivalents stood at $38.8 million in 2021, then crashed by 62.52% to $14.6 million in 2022, then grew by 1.76% to $14.8 million in 2023, then skyrocketed by 59.98% to $23.7 million in 2024, then soared by 231.03% to $78.4 million in 2025.
  • The last three reported values for Cash & Equivalents were $78.4 million (Q4 2025), $82.9 million (Q3 2025), and $163.9 million (Q2 2025) per Business Quant data.